<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CLEOCIN- clindamycin phosphate suppository </strong><br>U.S. Pharmaceuticals<br></p></div>
<h1>Cleocin<span class="Sup">®</span> Vaginal Ovules<br>(clindamycin phosphate vaginal suppositories)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">FOR INTRAVAGINAL USE ONLY</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Clindamycin phosphate is a water-soluble ester of the semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin. The chemical name for clindamycin phosphate is methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-<span class="Italics">trans</span>-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-<span class="Italics">threo-α-D-galacto</span>-octopyranoside 2-(dihydrogen phosphate). The monohydrate form has a molecular weight of 522.98, and the molecular formula is C<span class="Sub">18</span>H<span class="Sub">34</span>ClN<span class="Sub">2</span>O<span class="Sub">8</span>PS•H<span class="Sub">2</span>O. The structural formula is represented below:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c72f21f8-c81a-4e4c-9c98-ed46a57b3343&amp;name=cleocin-ovules-01.jpg"></div>
<p>CLEOCIN Vaginal Ovules are semisolid, white to off-white suppositories for intravaginal administration. Each 2.5 g suppository contains clindamycin phosphate equivalent to 100 mg clindamycin in a base consisting of a mixture of glycerides of saturated fatty acids.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Clin_Pharm"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Systemic absorption of clindamycin was estimated following a once-a-day intravaginal dose of one clindamycin phosphate vaginal suppository (equivalent to 100 mg clindamycin) administered to 11 healthy female volunteers for 3 days. Approximately 30% (range 6% to 70%) of the administered dose was absorbed systemically on day 3 of dosing based on area under the concentration-time curve (AUC). Systemic absorption was estimated using a subtherapeutic 100 mg intravenous dose of clindamycin phosphate as a comparator in the same volunteers. The mean AUC following day 3 of dosing with the suppository was 3.2 µg•hr/mL (range 0.42 to 11 µg•hr/mL). The C<span class="Sub">max</span> observed on day 3 of dosing with the suppository averaged 0.27 µg/mL (range 0.03 to 0.67 µg/mL) and was observed about 5 hours after dosing (range 1 to 10 hours). In contrast, the AUC and C<span class="Sub">max</span> after the single intravenous dose averaged 11  µg hr/mL (range 5.1 to 26 µg•hr/mL) and 3.7 µg/mL (range 2.4 to 5.0 µg/mL), respectively. The mean apparent elimination half-life after dosing with the suppository was 11 hours (range 4 to 35 hours) and is considered to be limited by the absorption rate.</p>
<p>The results from this study showed that systemic exposure to clindamycin (based on AUC) from the suppository was, on average, three fold lower than that from a single subtherapeutic 100 mg intravenous dose of clindamycin. In addition, the recommended daily and total doses of intravaginal clindamycin suppository are far lower than those typically administered in oral or parenteral clindamycin therapy (100 mg of clindamycin per day for 3 days equivalent to about 30 mg absorbed per day from the ovule relative to 600 to 2700 mg/day for up to 10 days or more, orally or parenterally). The overall systemic exposure to clindamycin from Cleocin Vaginal Ovules is substantially lower than the systemic exposure from therapeutic doses of oral clindamycin hydrochloride (two-fold to 20-fold lower) or parenteral clindamycin phosphate (40-fold to 50-fold lower).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4"></a><p></p>
<h1>MICROBIOLOGY</h1>
<p class="First">Clindamycin inhibits bacterial protein synthesis at the level of the bacterial ribosome. The antibiotic binds preferentially to the 50S ribosomal subunit and affects the process of peptide chain initiation. Although clindamycin phosphate is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin.</p>
<p>Culture and sensitivity testing of bacteria are not routinely performed to establish the diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>. (See <a href="#Indications_and_Usage">INDICATIONS AND USAGE</a>.) Standard methodology for the susceptibility testing of the potential <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> pathogens, <span class="Italics">Gardnerella vaginalis</span>, <span class="Italics">Mobiluncus</span> spp, or <span class="Italics">Mycoplasma hominis</span>, has not been defined. Nonetheless, clindamycin is an antimicrobial agent active in vitro against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms that have been reported to be associated with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>:</p>
<ul>
<li>
<span class="Italics">Bacteroides</span> spp</li>
<li><span class="Italics">Gardnerella vaginalis</span></li>
<li>
<span class="Italics">Mobiluncus</span> spp</li>
<li><span class="Italics">Mycoplasma hominis</span></li>
<li>
<span class="Italics">Peptostreptococcus</span> spp</li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Indications_and_Usage"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">CLEOCIN Vaginal Ovules are indicated for 3-day treatment of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> in non-pregnant women. There are no adequate and well-controlled studies of CLEOCIN Vaginal Ovules in pregnant women.</p>
<p><span class="Bold">NOTE</span>: For purposes of this indication, a clinical diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> is usually defined by the presence of a homogeneous <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> include (a) markedly reduced or absent <span class="Italics">Lactobacillus</span> morphology, (b) predominance of <span class="Italics">Gardnerella</span> morphotype, and (c) absent or few white blood cells.</p>
<p>Other pathogens commonly associated with <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">vulvovaginitis</span>, eg, <span class="Italics">Trichomonas vaginalis</span>, <span class="Italics">Chlamydia trachomatis</span>, <span class="Italics">Neisseria gonorrhoeae</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span>, and herpes simplex virus, should be ruled out.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">CLEOCIN Vaginal Ovules are contraindicated in individuals with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to clindamycin, lincomycin, or any of the components of this vaginal suppository. CLEOCIN Vaginal Ovules are also contraindicated in individuals with a history of <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">regional enteritis</span>, <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, or a history of "antibiotic-associated" <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with nearly all antibacterial agents, including clindamycin, and may range in severity from mild to life-threatening. Orally and parenterally administered clindamycin has been associated with severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, which may end fatally. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (including <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>) have been reported with the use of orally and parenterally administered clindamycin, as well as with topical (dermal) formulations of clindamycin. Therefore, it is important to consider this diagnosis in patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of CLEOCIN Vaginal Ovules, because approximately 30% of the clindamycin dose is systemically absorbed from the vagina.</span></p>
<p>Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by <span class="Italics">Clostridium difficile</span> is a primary cause of "antibiotic-associated" <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>After the diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established, therapeutic measures should be initiated. Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to discontinuation of the drug alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against <span class="Italics">Clostridium difficile</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p><span class="Bold">Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antimicrobial treatment.</span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">The use of CLEOCIN Vaginal Ovules may result in the overgrowth of nonsusceptible organisms in the vagina. In clinical studies using CLEOCIN Vaginal Ovules, treatment-related <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span> was reported in 2.7% and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> in 3.6% of 589 nonpregnant women. <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Moniliasis</span>, as reported here, includes the terms: vaginal or nonvaginal <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span> and <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>. <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span> includes the terms: <span class="product-label-link" type="condition" conceptid="4051956" conceptname="Vulvovaginal disease">vulvovaginal disorder</span>, <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span>, and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>/<span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infection</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.2"></a><p></p>
<h2>Information for the Patient</h2>
<p class="First">The patient should be instructed not to engage in vaginal intercourse or use other vaginal products (such as tampons or douches) during treatment with this product.</p>
<p><span class="Bold">The patient should also be advised that these suppositories use an oleaginous base that may weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms. Therefore, the use of such products within 72 hours following treatment with CLEOCIN Vaginal Ovules is not recommended.</span></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Systemic clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential. Genotoxicity tests performed included a rat micronucleus test and an Ames test. Both tests were negative. Fertility studies in rats treated orally with up to 300 mg/kg/day (31 times the human exposure based on mg/m<span class="Sup">2</span>) revealed no effects on fertility or mating ability.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.5.1"></a><p></p>
<h3>Teratogenic effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.1.1"></a><p></p>
<h4>Pregnancy Category B</h4>
<p class="First">In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities.</p>
<p>Clindamycin vaginal ovules should be used during the first trimester of pregnancy only if clearly needed and the benefits outweigh the risks. There are no adequate and well-controlled studies of CLEOCIN Vaginal Ovules in pregnant women during the first trimester of pregnancy.</p>
<p>CLEOCIN Vaginal Cream, 2%, has been studied in pregnant women during the second trimester. In women treated for 7 days, <span class="product-label-link" type="condition" conceptid="437342" conceptname="Abnormality of forces of labor">abnormal labor</span> was reported more frequently in patients who received CLEOCIN Vaginal Cream compared to those receiving placebo (1.1% vs. 0.5% of patients, respectively).</p>
<p>Reproduction studies have been performed in rats and mice using oral and parenteral doses of clindamycin up to 600 mg/kg/day (62 and 25 times, respectively, the maximum human dose based on body surface area) and have revealed no evidence of harm to the fetus due to clindamycin. <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">Cleft palates</span> were observed in fetuses from one mouse <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> treated intraperitoneally with clindamycin at 200 mg/kg/day (about 10 times the recommended dose based on body surface area conversions). Since this effect was not observed in other mouse <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> or in other species, the effect may be <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> specific.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Clindamycin has been detected in human milk after oral or parenteral administration. It is not known if clindamycin is excreted in human milk following the use of vaginally administered clindamycin phosphate.</p>
<p>Because of the potential for serious adverse reactions in nursing infants from clindamycin phosphate, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and efficacy of CLEOCIN Vaginal Ovules in the treatment of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> in post-menarchal females have been established on the extrapolation of clinical trial data from adult women. When a post-menarchal adolescent presents to a health professional with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> symptoms, a careful evaluation for <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span> and other risk factors for <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> should be considered. The safety and efficacy of CLEOCIN Vaginal Ovules in pre-menarchal females have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of CLEOCIN Vaginal Ovules did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Adverse_Reactions"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34092-7">
<a name="section-9.1"></a><p></p>
<h2>Clinical Trials</h2>
<p class="First">In clinical trials, 3 (0.5%) of 589 nonpregnant women who received treatment with CLEOCIN Vaginal Ovules discontinued therapy due to drug-related adverse events. Adverse events judged to have a reasonable possibility of having been caused by clindamycin phosphate vaginal suppositories were reported for 10.5% of patients. Events reported by 1% or more of patients receiving CLEOCIN Vaginal Ovules were as follows:</p>
<p><span class="Bold Italics">Urogenital system</span>: <span class="product-label-link" type="condition" conceptid="4051956" conceptname="Vulvovaginal disease">Vulvovaginal disorder</span> (3.4%), <span class="product-label-link" type="condition" conceptid="4244072" conceptname="Vaginal pain">vaginal pain</span> (1.9%), and <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal moniliasis</span> (1.5%).</p>
<p><span class="Bold Italics">Body as a whole</span>: <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infection</span> (1.0%).</p>
<p>Other events reported by &lt;1% of patients included:</p>
<p><span class="Italics">Urogenital system</span>: <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">Menstrual disorder</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span>, <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span>, and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>/<span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infection</span>.</p>
<p><span class="Italics">Body as a whole</span>: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal cramps</span>, localized <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">flank pain</span>, generalized <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4026047" conceptname="Sacral edema">localized edema</span>, and <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>.</p>
<p><span class="Italics">Digestive system</span>: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="Italics">Skin</span>: Nonapplication-site pruritis, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, application-site <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and application-site pruritis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Other clindamycin formulations</h2>
<p class="First">The overall systemic exposure to clindamycin from CLEOCIN Vaginal Ovules is substantially lower than the systemic exposure from therapeutic doses of oral clindamycin hydrochloride (two-fold to 20-fold lower) or parenteral clindamycin phosphate (40-fold to 50-fold lower). (See <a href="#Clin_Pharm">CLINICAL PHARMACOLOGY</a>.) Although these lower levels of exposure are less likely to produce the common reactions seen with oral or parenteral clindamycin, the possibility of these and other  reactions cannot be excluded.</p>
<p>The following adverse reactions and altered laboratory tests have been reported with the <span class="Bold">oral or parenteral</span> use of clindamycin and may also occur following administration of CLEOCIN Vaginal Ovules:</p>
<p><span class="Italics">Gastrointestinal</span>: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>. (See <a href="#Warnings">WARNINGS</a>.)</p>
<p><span class="Italics">Hematopoietic</span>: Transient <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>), <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> have been reported. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of these reports.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span>: <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">Maculopapular rash</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have been observed during drug therapy. Generalized mild to moderate morbilliform-like <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> are the most frequently reported of all adverse reactions. Rare instances of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, some resembling <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, have been associated with clindamycin. A few cases of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been reported. If a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> occurs, the drug should be discontinued.</p>
<p><span class="Italics">Liver</span>: <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> and abnormalities in liver function tests have been observed during clindamycin therapy.</p>
<p><span class="Italics">Musculoskeletal</span>: Rare instances of <span class="product-label-link" type="condition" conceptid="4025831" conceptname="Arthritis mutilans">polyarthritis</span> have been reported.</p>
<p><span class="Italics">Renal</span>: Although no direct relationship of clindamycin to renal damage has been established, renal dysfunction as evidenced by <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and/or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> has been observed in rare instances.</p>
<p>There have been reports of pseudomembranous colits following the administration of clindamycin vaginal cream.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Vaginally applied clindamycin phosphate contained in CLEOCIN Vaginal Ovules could be absorbed in sufficient amounts to produce systemic effects. (See <a href="#Warnings">WARNINGS</a> and <a href="#Adverse_Reactions">ADVERSE REACTIONS</a>.)</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose is one CLEOCIN Vaginal Ovule (containing clindamycin phosphate equivalent to 100 mg clindamycin per 2.5 g suppository) intravaginally per day, preferably at bedtime, for 3 consecutive days.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">CLEOCIN Vaginal Ovules are supplied as follows:</p>
<table width="75%">
<col align="left" valign="middle" width="60%">
<col align="right" valign="middle" width="40%">
<tbody class="Headless"><tr class="First Last">
<td align="left">Carton of three suppositories with one applicator</td>
<td align="right">NDC 0009-7667-01</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Important Information</span>: Store at 25°C (77°F); excursions permitted to 15 – 30°C (59 – 86°F) [see USP Controlled Room Temperature].</p>
<p><span class="Bold">Caution</span>: Avoid heat over 30°C (86°F). Avoid high humidity. See end of carton for the lot number and expiration date.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
<p>This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com.</p>
<div class="Figure"><img alt="Pfizer Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c72f21f8-c81a-4e4c-9c98-ed46a57b3343&amp;name=cleocin-ovules-02.jpg"></div>
<p>LAB-0047-4.0</p>
<p>January 2015</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-14"></a><p></p>
<h1>Cleocin<span class="Sup">®</span> Vaginal Ovules<br>(clindamycin phosphate vaginal suppositories)</h1>
<p class="First"><span class="Bold">FOR INTRAVAGINAL USE ONLY</span></p>
<p><span class="Bold">DIRECTIONS FOR USE</span></p>
<p><span class="Bold">How do I use CLEOCIN Vaginal Ovules?</span></p>
<p>For vaginal use only. Do not take by mouth.</p>
<p>Use one CLEOCIN Vaginal Ovule daily, preferably at bedtime, for 3 days in a row.</p>
<p>Do not use this product if the foiled pouches containing vaginal ovules are torn, opened, or incompletely sealed.</p>
<p>Read the full directions below before using.</p>
<p><span class="Bold">Insertion with the applicator</span>:</p>
<dl>
<dt>1.</dt>
<dd>Remove the vaginal ovule from its packaging. (See Figure 1.)</dd>
</dl>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c72f21f8-c81a-4e4c-9c98-ed46a57b3343&amp;name=cleocin-ovules-03.jpg"></div>
<dl>
<dt>2.</dt>
<dd>Pull back the plunger about an inch and place the vaginal ovule in the wider end of the applicator barrel. (See Figure 2.)</dd>
</dl>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c72f21f8-c81a-4e4c-9c98-ed46a57b3343&amp;name=cleocin-ovules-04.jpg"></div>
<dl>
<dt>3.</dt>
<dd>Hold the applicator as shown and gently insert the end of the applicator into the vagina as far as it will go comfortably. This can be done while lying on your back with your knees bent (as shown in Figure 3), or while standing with your feet apart and your knees bent.</dd>
</dl>
<div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c72f21f8-c81a-4e4c-9c98-ed46a57b3343&amp;name=cleocin-ovules-05.jpg"></div>
<dl>
<dt>4.</dt>
<dd>While holding the barrel of the applicator in place, push the plunger in until it stops to release the vaginal ovule. Remove the applicator from the vagina.</dd>
</dl>
<dl>
<dt>5.</dt>
<dd>Clean the applicator after each use. Pull the two pieces apart and wash them with soap and warm water. Rinse well and dry. Put the two pieces back together and store in a clean, dry place.</dd>
</dl>
<dl>
<dt>6.</dt>
<dd>Once inside the vagina, the ovule melts. Lie down as soon as possible. This will keep leakage to a minimum.</dd>
</dl>
<dl>
<dt>7.</dt>
<dd>Repeat steps 1 through 6, before bedtime, for the next 2 days.</dd>
</dl>
<p><span class="Bold">Insertion without the applicator</span>:</p>
<ol>
<li>Remove the vaginal ovule from its packaging. (See Figure 1.)</li>
<li>Holding the ovule with your thumb and a finger, insert it into the vagina.</li>
<li>Using your finger, gently push the ovule into the vagina as far as it will comfortably go.</li>
<li>Once inside the vagina, the ovule melts. Lie down as soon as possible. This will keep leakage to a minimum.</li>
<li>Repeat steps 1 through 4, before bedtime, for the next 2 days.</li>
</ol>
<p><span class="Bold">STORAGE CONDITIONS:</span></p>
<p>Store at 25°C (77°F); excursions permitted to 15 – 30°C (59 – 86°F) [see USP Controlled Room Temperature]. <span class="Bold">Caution</span>: Avoid heat over 30°C (86°F). Avoid high humidity. See end of carton for the lot number and expiration date.</p>
<p>LAB-0649-1.0<br>December 2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</h1>
<p class="First"><span class="Bold">PROFESSIONAL SAMPLE - NOT FOR SALE</span></p>
<p><span class="Bold">Cleocin<span class="Sup">®</span></span> 100 mg<br>clindamycin phosphate<br>vaginal suppositories<br>Keep Out of Reach of Children <br>U.S. Pharmaceuticals Pfizer Inc, NY, NY 10017</p>
<p>Lot<br>Exp</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c72f21f8-c81a-4e4c-9c98-ed46a57b3343&amp;name=cleocin-ovules-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Carton</h1>
<p class="First"><span class="Bold">PROFESSIONAL SAMPLE - NOT FOR SALE</span></p>
<p>NDC 63539-011-01</p>
<p><span class="Bold Italics">Pfizer</span></p>
<p><span class="Bold">Cleocin</span><span class="Sup">®</span><br><span class="Bold">Vaginal Ovules</span></p>
<p>equivalent to<br><span class="Bold">100 mg*</span><br>clindamycin</p>
<p>(clindamycin phosphate<br>vaginal suppositories)</p>
<p>For Intravaginal Use Only</p>
<p>3 Suppositories with one applicator</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c72f21f8-c81a-4e4c-9c98-ed46a57b3343&amp;name=cleocin-ovules-07.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CLEOCIN 		
					</strong><br><span class="contentTableReg">clindamycin phosphate suppository</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63539-011</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">VAGINAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLINDAMYCIN PHOSPHATE</strong> (CLINDAMYCIN) </td>
<td class="formItem">CLINDAMYCIN</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63539-011-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050767</td>
<td class="formItem">08/13/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>U.S. Pharmaceuticals
							(829076905)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Chongqing Carelife Pharmaceutical Co., Ltd</td>
<td class="formItem"></td>
<td class="formItem">531132009</td>
<td class="formItem">API MANUFACTURE(63539-011)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmacia and Upjohn Company</td>
<td class="formItem"></td>
<td class="formItem">829076566</td>
<td class="formItem">ANALYSIS(63539-011), API MANUFACTURE(63539-011), LABEL(63539-011), MANUFACTURE(63539-011), PACK(63539-011)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>95885e5b-1bce-4de0-95fd-42facae7ecc4</div>
<div>Set id: c72f21f8-c81a-4e4c-9c98-ed46a57b3343</div>
<div>Version: 1</div>
<div>Effective Time: 20150914</div>
</div>
</div> <div class="DistributorName">U.S. Pharmaceuticals</div></p>
</body></html>
